This was concluded by undergoing a study by Drs Kirsti Nanto-Salonen and Olli Simell, of the University of Turku, Finland, and colleagues involving 116720 cord blood samples of infants and 3430 of their siblings. Then 264 children (224 index/40 siblings) were entered into the controlled study, who were tested positive for two or more autoantibodies in consecutive samples 3-6 months apart.
Of these, 115 index/22 siblings were in the insulin group (dose 1 unit/kg), and 109 index/18 siblings in the placebo group.
The researchers found that similar numbers of index children from both groups were diagnosed with type I diabetes : 49 insulin versus 47 placebo; 42 and 38 of those were children.
Thus concluding that nasal insulin administration did not delay or prevent type I diabetes in children.
This research work is published online in the upcoming edition of The Lancet.